💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Vildagliptin

CHEMBL142703 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
303.4 g/mol
LogP
0.9
Phase
4

Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prevents the enzymatic degradation of incretin hormones GLP-1 and GIP, prolonging their physiological effects of glucose-dependent insulin secretion stimulation and glucagon suppression to improve glycemic control in type 2 diabetes. It is used as monotherapy or in combination with metformin, sulfonylureas, or insulin for type 2 diabetes management. DPP-4 inhibition provides glucose-dependent hypoglycemic effects with low risk of hypoglycemia.

الوزن الجزيئي

303,4000 g/mol

LogP

0,90

TPSA

76,40 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Thyroid Cancer Cardiovascular Disease Osteoporosis Schizophrenia Non-Alcoholic Fatty Liver Disease Stroke Obesity Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Heart Failure

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2

                

                

                
                

                    
InChI

                    
InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C17H25N3O2

                    

                    
                    

                        
HBD / HBA

                        
2 / 4

                    

                    
                    

                        
الروابط القابلة للدوران

                        
3

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
22

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prevents the enzymatic degradation of incretin hormones GLP-1 and GIP, prolonging their physiological effects of glucose-dependent insulin secretion stimulation and glucagon suppression to improve glycemic control in type 2 diabetes. It is used as monotherapy or in combination with metformin, sulfonylureas, or insulin for type 2 diabetes management. DPP-4 inhibition provides glucose-dependent hypoglycemic effects with low risk of hypoglycemia.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Vildagliptin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL142703.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6918537.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.